Eric Rubin

Eric Joseph Rubin (born 1958) is an American microbiologist, and infectious disease specialist. He is a professor of medicine at Harvard Medical School, an adjunct professor of immunology and infectious diseases at the Harvard T.H. Chan School of Public Health and the editor-in-chief of the New England Journal of Medicine and NEJM Group.

Personal life Rubin was born and raised in Brockton, Massachusetts. His father, Morris Rubin, was a salesman and his mother, Paula (Schechet) Rubin, was a school librarian. He is married to Akiyo Fujii and has two children, Alexander and Daniel.

Education and career Rubin graduated from Brockton High School, Harvard College (AB, 1980) and Tufts University (MD and PhD, 1990). As a graduate student he studied the mechanism of action of botulinum toxins with Dr. Michael Gill. Rubin trained in internal medicine and infectious disease at the Massachusetts General Hospital and went on to postdoctoral work in John Mekalanos lab at Harvard Medical School. There he studied Vibrio cholerae, Haemophilus influenzae and Mycobacterium smegmatis.

Rubin joined the Department of Immunology and Infectious Diseases at the Harvard T.H. Chan School of Public Health in 1999, eventually becoming the Irene Heinz Given Professor and Chair of the Department. His lab studies mycobacterial physiology and virulence and has developed many of the genetic tools used to study Mycobacterium tuberculosis and related organisms. With collaborators, the lab has used these tools to address a wide range of questions about tuberculosis pathogenesis, non-tuberculous mycobacteria, and drug and vaccine development. He is also an infectious disease clinician who sees patients at Brigham and Women’s Hospital, where he is an associate physician. and rapidly published many studies, including the first description of SARS-CoV-2, the causative virus. Under his editorial leadership, NEJM Group launched NEJM Evidence (2022) and NEJM AI (2023), a monthly journal that explores cutting-edge applications of artificial intelligence and machine learning in clinical medicine. He also oversees NEJM Catalyst Innovations in Care Delivery and NEJM Clinician, which launched in December 2025.

Rubin has worked extensively in international settings and has been involved on advisory boards for several national and global organizations. He is a member of the American Academy of Microbiology, the American Association of Physicians, and the National Academy of Medicine.